4CPS-223 Real world experience of selexipag for pulmonary arterial hypertension

Abstract

Conclusion and relevance DOAC use increased notably in our PC area during the SARS-CoV-2 pandemic. We found that 40.2% of patients treated with DOAC had at least one contraindication for the treatment. Interventions should be done to improve DOAC prescription and ensure patient safety.